Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Napredek zdravljenja bolnikov z razsejanim rakom debelega črevesa in danke z vidika internista onkologa
Authors:Ocvirk, Janja (Author)
Language:Slovenian
Tipology:1.08 - Published Scientific Conference Contribution
Organisation:Logo OI - Institute of Oncology
Abstract:Metastatski rak debelega črevesa in danke je v večini primerov še vedno neozdravljiva bolezen, vendar pa sta se prognoza ter preživetje teh bolnikov močno izboljšala v zadnjem desetletju. Od srednjega desetmesečnega preživetja, ki smo ga dosegali z zdravljenjem s 5-fluorouracilom, ki je bilo do pred nekaj leti edino učinkovito zdravilo za zdravljenje teh bolnikov, smo prešli na preživetja daljša od 20 mesecev, kar so omogočila nova citostatska zdravila. V zadnjih desetih letih je bilo registriranih šest novih zdravil za zdravljenje matastatskega raka debelega črevesa in danke: citostatiki - kapecitabin, irinotekan, oksaliplatin in tarčna zdravila - cetuksimab, bevacizumab in panitumumab. Kombinirano zdravljenje omogoča boljšo kakovost življenja in daljše remisije, s tem pa tudi daljša celotna preživetja. Uporaba kombinacije citostatikov s tarčnimi zdravili vodi še v nadaljnje podaljšanje srednjega preživetja teh bolnikov, tako zdravljeni bolniki imajo srednja preživetja daljša od 30 mesecev. Tovrstno zdravljenje, v kombinaciji z operacijo pljučnih ali jetrnih zasevkov, pa omogoča tudi zazdravitve. Pomembno je določanje mutacij na genu KRAS. Za kolorektalni rak je gen KRAS prvi biomarker, ki napoveduje, kako se bodo bolniki odzvali na zdravljenja z EGFR inhibitorji.
Keywords:razsejani rak, rak debelega črevesa, rak danke, internistična onkologija
Year of publishing:2013
COBISS_ID:1555067 Link is opened in a new window
UDC:616.3-006-08
ISSN on article:1408-1741
OceCobissID:1553275 Link is opened in a new window
URN:URN:NBN:SI:doc-CJ0TK1YB
Views:1469
Downloads:342
Files:.pdf PDF - Presentation file, download (320,32 KB)
 
Journal:Šola tumorjev prebavil, Ljubljana, 30. 11. 2012
Onkološki inštitut
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:by Authors
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Progress in the treatment of patients with metastatic colorectal cancer from the perspective of an medical oncologist
Abstract:Metastatic colorectal cancer is in the majority of cases still an incurable disease, but the prognosis and the survival of these patients have improved considerably in the last decade. From the median survival of 10 months achieved with 5-fluorouracil, which had been, until few years ago, the only effective drug for the treatment of these patients, we have obtained survival times of more than 20 months as a result of treatment with new cytostatic drugs. In the last ten years, six new drugs were registered for the treatment of metastatic colorectal cancer: cytostatics – capecitabine, irinotecan, oxaliplatin, and target drugs – cetuximab, bevacizumab and panitumumab. Combined treatment assures a better quality of life and longer remissions, and also increased overall survival. Combining cytostatics with target drugs further improves the median survival of these patients, and patients undergoing treatment have a median survival of more than 30 months. Such treatment in combination with surgery of lung or liver metastases also enables remissions. Identification of mutations in the KRAS gene is of utmost importance. For colorectal cancer, the KRAS gene is the first biomarker that predicts the response of patients to treatment with EGFR inhibitors.

Archive

niGradiv

Back